Finch Therapeutics Group, Inc. (NASDAQ:FNCH – Get Rating) was the target of a significant drop in short interest in the month of July. As of July 15th, there was short interest totalling 285,900 shares, a drop of 24.5% from the June 30th total of 378,600 shares. Based on an average daily volume of 968,000 shares, the short-interest ratio is currently 0.3 days. Currently, 1.9% of the shares of the company are sold short.
Finch Therapeutics Group Stock Performance
Finch Therapeutics Group stock traded up $0.17 during midday trading on Wednesday, reaching $2.07. 5 shares of the company's stock were exchanged, compared to its average volume of 39,337. Finch Therapeutics Group has a 52 week low of $1.71 and a 52 week high of $17.39. The firm has a market cap of $98.45 million, a price-to-earnings ratio of -1.43 and a beta of -0.52. The stock's 50-day simple moving average is $2.44 and its 200 day simple moving average is $4.50.
Get
Finch Therapeutics Group alerts:
Finch Therapeutics Group (NASDAQ:FNCH – Get Rating) last posted its quarterly earnings results on Monday, May 16th. The company reported ($0.52) EPS for the quarter. The business had revenue of $0.35 million for the quarter. Finch Therapeutics Group had a negative return on equity of 33.13% and a negative net margin of 448.35%. Research analysts forecast that Finch Therapeutics Group will post -1.98 earnings per share for the current year.
Institutional Investors Weigh In On Finch Therapeutics Group
Several hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its position in Finch Therapeutics Group by 19.4% during the first quarter. Renaissance Technologies LLC now owns 45,000 shares of the company's stock worth $226,000 after acquiring an additional 7,314 shares during the last quarter. BlackRock Inc. lifted its position in Finch Therapeutics Group by 2.3% during the first quarter. BlackRock Inc. now owns 404,931 shares of the company's stock worth $2,038,000 after acquiring an additional 9,149 shares during the last quarter. Qube Research & Technologies Ltd lifted its position in Finch Therapeutics Group by 53.6% during the first quarter. Qube Research & Technologies Ltd now owns 37,631 shares of the company's stock worth $189,000 after acquiring an additional 13,128 shares during the last quarter. Light Street Capital Management LLC lifted its position in Finch Therapeutics Group by 1.8% during the fourth quarter. Light Street Capital Management LLC now owns 811,731 shares of the company's stock worth $8,093,000 after acquiring an additional 14,400 shares during the last quarter. Finally, SCS Capital Management LLC acquired a new stake in Finch Therapeutics Group during the fourth quarter worth approximately $382,000. 22.68% of the stock is currently owned by institutional investors and hedge funds.
About Finch Therapeutics Group
(Get Rating)
Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus.
Further Reading
- Get a free copy of the StockNews.com research report on Finch Therapeutics Group (FNCH)
- Is Starbucks Shooting For The Moon?
- PayPal Continues To Struggle As Competition Increases
- Two High-Yield Deep-Values You Shouldn't Ignore
- Proposed Tesla Stock Split Drives EV Market Higher
- Caterpillar Falls To Strong Support Near Bottom Of Range
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.
